Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients

Journal of Infectious Diseases

Volumn 203, Issue 8, 2011, Pages 1087-1095

  Yoneda, Suguru ^a   Umemura, Takeji ^a   Katsuyama, Yoshihiko ^b   Kamijo, Atsushi ^a   Joshita, Satoru ^a   Komatsu, Michiharu ^a   Ichijo, Tetsuya ^a   Matsumoto, Akihiro ^a   Yoshizawa, Kaname ^a   Ota, Masao ^a   Tanaka, Eiji ^a   Miyabayashi, Chiharu ^c   Koike, Yuriko ^d  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

^c Chikuma Central Hospital   (Japan)

^d Kawanakajima Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CORE PROTEIN; GLUTAMIC ACID; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INTERFERON SENSITIVITY DETERMINING REGION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; VIRUS CORE REGION;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CYTOKINES; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; VIRAL CORE PROTEINS;

EID: 79953300072     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq165     Document Type: Article

References (42)

1. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321:1494-500. (Pubitemid 20015539)
2. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671-5. (Pubitemid 20349249)
3. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007; 37:S95-S100.
4. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009; 44:102-7.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358:958-65. (Pubitemid 32913521)
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
7. Wan L, Kung YJ, Lin YJ, et al. Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-a. Biochem Biophys Res Commun 2009; 379:855-60.
8. Umemura T, Wang RY, Schechterly C, Shih JW, Kiyosawa K, Alter HJ. Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 2006; 43:91-9. (Pubitemid 43733595)
9. Umemura T, Zen Y, Hamano H, Kawa S, Nakanuma Y, Kiyosawa K. Immunoglobin G4-hepatopathy: Association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007; 46:463-71. (Pubitemid 47344782)
10. Shirakawa H, Matsumoto A, Joshita S, et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors. Hepatology 2008; 48:1753-60.
11. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48:372-80. (Pubitemid 41003622)
12. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87:9524-8. (Pubitemid 120016475)
13. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81. (Pubitemid 26017933)
14. Kuzushita N, Hayashi N, Katayama K, et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 1997; 32:169-74. (Pubitemid 27075123)
15. Marín-Serrano E, Rodríguez-Ramos C, Díaz F, Martín-Herrera L, Girón-González JA. Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat 2006; 13:230-4.
16. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6:578-82. (Pubitemid 30305910)
17. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081-95.
18. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-51.
19. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8:1390-7. (Pubitemid 350138974)
20. Stumhofer JS, Silver JS, Laurence A, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007; 8:1363-71. (Pubitemid 350131173)
21. Crawley E, Kon S, Woo P. Hereditary predisposition to low interleukin-10 production in children with extended oligoarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2001; 40:574-8.
22. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Höhler T. Differential regulation of interleukin-10 production by genetic and environmental factors-a twin study. Genes Immun 2002; 3:407-13. (Pubitemid 41656539)
23. Oleksyk TK, Thio CL, Truelove AL, et al. Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance. Genes Immun 2005; 6:347-57. (Pubitemid 40903408)
24. Paladino N, Fainboim H, Theiler G, et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol 2006; 80:9144-50. (Pubitemid 44359986)
25. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30:526-30. (Pubitemid 29357520)
26. Yee LJ, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001; 33:708-12. (Pubitemid 32185234)
27. Knapp S, Hennig BJ, Frodsham AJ, et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003; 55:362-9. (Pubitemid 37255487)
28. Morgan TR, Lambrecht RW, Bonkovsky HL, et al. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: Results from the HALT-C trial. J Hepatol 2008; 49:548-56.
29. Mori N, Imamura M, Kawakami Y, et al. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J Med Virol 2009; 81:640-9.
30. Kurbanov F, Tanaka Y, Matsuura K, et al. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin. J Infect Dis 2010; 201:1663-71.
31. Nakagawa M, Sakamoto N, Ueyama M, et al. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. J Gastroenterol 2010; 45:656-65.
32. Hayashi K, Katano Y, Ishigami M, et al. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy [published online ahead of print 28 March 2010]. J Viral Hepat. doi: 10.1111/j.1365-2893. 2010.01305.x.
33. Dolganiuc A, Kodys K, Kopasz A, et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 2003; 170:5615-24. (Pubitemid 36617852)
34. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13:251-76.
35. Rossol S, Marinos G, Carucci P, Singer MV, Williams R, Naoumov NV. Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B. J Clin Invest 1997; 99:3025-33. (Pubitemid 27278680)
36. Quiroga JA, Martín J, Navas S, Carreño V. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage. J Infect Dis 1998; 178:247-51. (Pubitemid 28328101)
37. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol 2001; 19:423-74. (Pubitemid 32368042)
38. Loffreda S, Muratori P, Muratori L, Mele L, Bianchi FB, Lenzi M. Enhanced monocyte Th1 cytokine production in HCV-infected cryoglobulinemic patients. J Hepatol 2003; 38:230-6. (Pubitemid 36169634)
39. Schvoerer E, Navas MC, Thumann C, et al. Production of interleukin-18 and interleukin-12 in patients suffering from chronic hepatitis C virus infection before antiviral therapy. J Med Virol 2003; 70:588-93. (Pubitemid 36734723)
40. Salcedo X, Medina J, Sanz-Cameno P, et al. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005; 42:696-701. (Pubitemid 41233664)
41. Cho ML, Jung YO, Moon YM, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 2006; 103:159-66. (Pubitemid 43162931)
42. Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10:355-62. (Pubitemid 40486931)